Flu vaccine strategies for adults with blood cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, controlled Phase 3 trial will assign adults with hematologic malignancies to receive one of three licensed influenza vaccines: high-dose trivalent (Efluelda), MF59-adjuvanted quadrivalent (Fluad Quadrivalent), or standard-dose trivalent. Immunogenicity will be compared using hemagglutination-inhibition antibody measures (GMT, seroconversion, seroprotection) and cellular assays quantifying polyfunctional CD4+ and CD8+ T-cell responses. Participants include patients with lymphoma, leukemia, plasma cell disorders, and those undergoing autologous stem cell transplantation or CAR-T therapy, with blood samples collected before vaccination and at scheduled follow-up visits. The trial aims to identify which formulation elicits the most robust humoral and cellular immunity in this severely immunocompromised population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged 19 years or older
* Confirmed diagnosis of hematologic malignancy, including:

non-Hodgkin lymphoma, Hodgkin lymphoma, acute leukemia, chronic leukemia, or plasma cell disorders

Exclusion Criteria:

* Difficulty with repeated venipuncture or blood sampling (e.g., poor vascular access or bleeding tendency)
* Cognitive or psychiatric impairment precluding understanding of or cooperation with study procedures
* Known hypersensitivity to influenza vaccine components
* Influenza vaccination within the preceding 6 months
* Any other condition deemed clinically inappropriate for study participation at investigator discretion

Where it's running

• Asan Medical Center
  Seoul, South Korea Recruiting

Study contacts

• Principal investigator: Sung-Han Kim, MD, PhD — Asan Medical Center
• Study coordinator: So Yun Lim, MD, PhD
• Email: soyun_lim@amc.seoul.kr
• Phone: +82-10-4120-3816

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-dose vs standard-dose flu vaccine in adults with blood cancers on B-cell-depleting therapy

  This study tests whether a high-dose flu shot evokes a stronger immune response than a standard-dose shot in adults with hematologic cancers who recently had B-cell-depleting therapy.

  Recruiting Phase 2 Asan Medical Center · Seoul · NCT07926217

• Abbott ID NOW at the point of care for flu-like illness in long-term care facilities

  This trial tests whether the Abbott ID NOW rapid test at the point of care in long-term care facilities can help identify influenza sooner for residents 65 and older with fever and respiratory symptoms.

  Recruiting China Medical University Hospital · Taichung · NCT07846423

• Influenza Vaccine Immunogenicity in Older Adults with Repeated Vaccination

  This study tests how different flu vaccines perform in adults 65+ who get yearly vaccines to see if age and repeated vaccination affect the immune response.

  Recruiting Phase 4 Korea University Guro Hospital · Seoul · NCT07838298

• Immunogenicity screening of Leishmania vaccine candidate antigens in Ethiopian patients

  This study tests whether six Leishmania vaccine candidate antigens can trigger T-cell responses in patients with cutaneous or visceral leishmaniasis.

  Recruiting at 2 sites Institute of Tropical Medicine, Belgium · Addis Ababa and 1 other locations · NCT07783243

• Egg-based H5N8 influenza vaccine at multiple doses with or without adjuvant in healthy adults

  This trial tests whether an egg-based H5N8 flu vaccine, given at low to high doses with or without an adjuvant, is safe and can provoke a stronger immune response in healthy adults 18 and older.

  Recruiting at 16 sites Phase 1/2 Sanofi · Tempe, Arizona and 15 other locations · NCT07779408

• Anti-CD25 antibody to prevent acute GVHD after haploidentical stem cell transplant

  This study tests whether an anti-CD25 antibody can better prevent acute graft-versus-host disease after haploidentical hematopoietic stem cell transplantation compared with the usual methotrexate-based approach.

  Recruiting Phase 3 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07689630

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.